Search

Your search keyword '"Takehara, Tetsuo"' showing total 2,162 results

Search Constraints

Start Over You searched for: Author "Takehara, Tetsuo" Remove constraint Author: "Takehara, Tetsuo"
2,162 results on '"Takehara, Tetsuo"'

Search Results

1. Proteomic analysis of serum extracellular vesicles reveals Fibulin-3 as a new marker predicting liver-related events in MASLD.

2. A machine learning model for predicting the lymph node metastasis of early gastric cancer not meeting the endoscopic curability criteria

3. A novel artificial intelligence-based endoscopic ultrasonography diagnostic system for diagnosing the invasion depth of early gastric cancer

4. Posttreatment liver function, but not baseline liver function stratifies patient survival after direct-acting antiviral treatment in decompensated cirrhosis with hepatitis C virus

8. The relationship between observation interval and prognosis in pancreatic cancer concomitant with intraductal papillary mucinous neoplasia

10. Plasma trough concentration of imatinib and its effect on therapeutic efficacy and adverse events in Japanese patients with GIST

11. Improved Liver Function After Sustained Virologic Response Enhanced Prognosis in Hepatitis C with Compensated Advanced Liver Fibrosis

12. Diagnostic value of endoscopic ultrasonography for the depth of gastric cancer suspected of submucosal invasion: a multicenter prospective study

13. Efficacy and safety of the siRNA JNJ-73763989 and the capsid assembly modulator JNJ-56136379 (bersacapavir) with nucleos(t)ide analogues for the treatment of chronic hepatitis B virus infection (REEF-1): a multicentre, double-blind, active-controlled, randomised, phase 2b trial

14. Non-Pure Intestinal Phenotype as an Indicator of Progression in Sporadic Non-ampullary Duodenal Adenomas: A Multicenter Retrospective Cohort Study

18. TOP-288 Serum GDF15 level, in combination with the FIB-4 index, is useful for refining the identification of high-risk patients for clinical event occurrence in MASLD patients

19. THU-413 Baseline gamma-glutamyl transpeptidase levels are associated with aggravation of esophagogastric varix after direct-acting antiviral therapy in cirrhotic patients with hepatitis C virus

20. Prokaryotic and viral genomes recovered from 787 Japanese gut metagenomes revealed microbial features linked to diets, populations, and diseases

21. Hepatitis C virus modulates signal peptide peptidase to alter host protein processing

22. Elderly onset age is associated with low efficacy of first anti-tumor necrosis factor treatment in patients with inflammatory bowel disease

23. Serum IL-1β predicts de novo hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C, not during anti-cancer/immunosuppressive therapy

25. Liver-related events after direct-acting antiviral therapy in patients with hepatitis C virus-associated cirrhosis

26. The serum tenascin C level is a marker of metabolic disorder-related inflammation affecting pancreatic cancer prognosis

27. High incidence of lung cancer death after curative endoscopic submucosal dissection for superficial esophageal squamous cell carcinoma

30. Evidence-based clinical practice guidelines for Liver Cirrhosis 2020

31. Leucine-rich alpha-2 glycoprotein is a potential biomarker to monitor disease activity in inflammatory bowel disease receiving adalimumab: PLANET study

35. Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials

37. Efficacy of prophylactic clip closure in reducing the risk of delayed bleeding after colorectal endoscopic submucosal dissection in patients on anticoagulant therapy: Multicenter prospective study

38. Genome‐wide loss‐of‐function genetic screen identifies INSIG2 as the vulnerability of hepatitis B virus‐integrated hepatoma cells

39. Utility and advantage of the unroofing technique for gastrointestinal subepithelial tumors: A multicenter retrospective cohort study

40. Clinical factors associated with the therapeutic efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma: A multicenter prospective observational study

42. Sofosbuvir plus velpatasvir treatment for hepatitis C virus in patients with decompensated cirrhosis: a Japanese real-world multicenter study

44. Vascular endothelial growth factor-A is an Immunohistochemical biomarker for the efficacy of bevacizumab-containing chemotherapy for duodenal and jejunal adenocarcinoma

46. JNJ-4178 (adafosbuvir, odalasvir, and simeprevir) in Japanese patients with chronic hepatitis C virus genotype 1 or 2 infection with or without compensated cirrhosis: the Phase IIa OMEGA-3 study

47. Effects of Zinc Acetate on Serum Zinc Concentrations in Chronic Liver Diseases: a Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial and a Dose Adjustment Trial

49. Molecular Genealogy of Metabolic-associated Hepatocellular Carcinoma.

50. The impact of the COVID‐19 pandemic on hepatocellular carcinoma diagnosis and treatment in Japan: A multicenter collaborative observational study.

Catalog

Books, media, physical & digital resources